Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($7.75) per share for the quarter.
Aptevo Therapeutics Trading Up 6.4 %
APVO stock opened at $3.82 on Friday. The company has a fifty day moving average price of $4.26 and a 200 day moving average price of $209.67. Aptevo Therapeutics has a 12 month low of $3.01 and a 12 month high of $399.60.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a research report on Monday, December 9th. They issued a “sell” rating for the company.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- What is a Bond Market Holiday? How to Invest and Trade
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
